AICAR Research Guide Ireland

Overview

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide), also known as acadesine, is a nucleotide analogue and cell-permeable precursor of ZMP, a molecule that mimics AMP within the cell. Through this mimicry, AICAR acts as a potent activator of AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism that is normally switched on by rising AMP levels during energy stress such as exercise or fasting. AICAR is a nucleotide analogue, not a peptide in the strict chemical sense, but it is catalogued and discussed alongside peptide research compounds due to overlapping research interest in metabolic and performance contexts. AICAR is widely discussed in exercise science and sports research circles as an "exercise mimetic," because pharmacological AMPK activation can reproduce some of the metabolic adaptations normally induced by endurance training — including increased mitochondrial biogenesis, enhanced fatty acid oxidation, and improved glucose uptake — without physical exertion. Separately, AICAR (under the name acadesine) has a genuine clinical research history: it was studied in human cardiac surgery trials during the 1990s and 2000s as a potential cardioprotective agent to reduce perioperative ischemic injury, a context entirely distinct from its exercise-mimetic research use. This guide is for educational and research purposes only. Not medical advice.

Clinical & Research Status

Evidence Type	Status
Human RCT	✔ (historical acadesine cardiac surgery cardioprotection trials — different indication to exercise-mimetic research)
Observational	✗
Animal Studies	✔
In Vitro	✔
Regulatory Approval	✗ (development discontinued after Phase 3 endpoints not met; never approved for any indication; also WADA-prohibited in sport)

Mechanism of Action

Once inside the cell, AICAR is converted by adenosine kinase into ZMP, an AMP-mimetic nucleotide. ZMP binds to the regulatory subunit of AMP-activated protein kinase (AMPK) in a manner that mimics rising cellular AMP, allosterically activating AMPK and promoting its phosphorylation by upstream kinases such as LKB1. This activation occurs independently of the actual cellular ATP/AMP energy ratio, meaning AICAR can switch on AMPK signalling pharmacologically, without the metabolic stress normally required to trigger it (such as exercise or caloric restriction). Downstream of AMPK activation, research has linked AICAR treatment to increased expression of PGC-1alpha, a transcriptional co-activator central to mitochondrial biogenesis, along with increased fatty acid oxidation and enhanced GLUT4 translocation to the cell membrane, which improves glucose uptake in muscle tissue. These downstream effects are the basis for AICAR's characterisation as an "exercise mimetic" in preclinical literature, since they overlap substantially with the adaptations produced by genuine endurance exercise training.

Research Areas & Reported Effects

AMPK Activation & Exercise Mimetic Research

The landmark study in this area is Narkar VA et al. 2008, published in Cell, from Ronald Evans' laboratory at the Salk Institute. This research demonstrated that AICAR, an AMPK activator, when combined with GW501516 (a PPAR-delta agonist), improved running endurance in sedentary mice, and that AICAR alone was sufficient to activate genes involved in oxidative metabolism. This is one of the most frequently cited papers establishing the "exercise mimetic" concept for AMPK-activating compounds.

Endurance & Fat Oxidation in Preclinical Models

Building on the AMPK activation mechanism, preclinical rodent studies report that AICAR administration increases markers of fatty acid oxidation and mitochondrial gene expression in skeletal muscle. In the Narkar et al. 2008 study specifically, sedentary mice treated with the combination of AICAR and GW501516 showed an improvement in treadmill running endurance of approximately 44% compared to untreated controls. All of this specific endurance and fat-oxidation research is rodent-based; it has not been validated in human athletic performance studies.

Historical Cardioprotection Research (Acadesine)

Separately from the exercise-mimetic research interest, AICAR — studied under the name acadesine — has a genuine history of human clinical investigation in cardiac surgery. Multicentre Phase 3 acadesine perioperative cardioprotection trials conducted during the 1990s and 2000s investigated whether the compound could reduce ischemic injury (such as myocardial infarction and stroke) during and after coronary artery bypass graft (CABG) surgery. While some trial contexts reported signals of reduced perioperative ischemic events, the overall Phase 3 results did not consistently meet regulatory endpoints, and acadesine development for this indication was ultimately discontinued without approval.

WADA Prohibited Status & Sport Compliance

AICAR is explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List as a metabolic modulator under the S4 class of prohibited substances. This means AICAR is banned in competitive sport at all times, and its use by athletes subject to anti-doping rules is a direct violation regardless of research or performance intent. This regulatory fact is separate from, and in addition to, the compound never having received any human regulatory approval for therapeutic or performance use.

Research Data Summary

Study / Model	Reported Effect
Narkar VA et al. 2008, Cell (sedentary mice, AICAR alone)	Activated genes involved in oxidative metabolism without additional pharmacological agents.
Narkar VA et al. 2008, Cell (sedentary mice, AICAR + GW501516 combination)	Improved treadmill running endurance by approximately 44% compared to untreated controls.
Historical multicentre acadesine perioperative cardioprotection trials (1990s–2000s)	Reported signals of reduced perioperative ischemic events (e.g. myocardial infarction) in some trial contexts; overall Phase 3 endpoints not consistently met, development discontinued, never approved.
In vitro / cell culture AMPK activation studies	Demonstrated potent AMPK activation via ZMP formation, supporting downstream effects on PGC-1alpha expression and GLUT4 translocation.

Stack Combinations Studied

• AICAR + GW501516 (PPAR-delta agonist) → Research rationale: This is the exact combination studied in the landmark Narkar VA et al. 2008 Cell paper. The rationale is dual-pathway activation — AICAR activates AMPK while GW501516 activates PPAR-delta, and the combination was reported to produce a larger improvement in treadmill endurance in sedentary mice than either compound alone, reflecting complementary effects on oxidative metabolism gene expression.

Beyond the AICAR + GW501516 combination directly studied by Narkar et al., limited additional stack-specific research exists for AICAR in the exercise-mimetic context. GW501516 itself is a separately controversial and WADA-banned research compound; combination research should be understood strictly as historical preclinical science, not a usage recommendation.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

experimental research protocols only — not dosing recommendations. No validated human dosing exists for AICAR in the exercise-mimetic/performance research context. The ranges below are loosely derived from rodent (mg/kg) research models for reference purposes only. A separate historical human IV dosing context exists from the acadesine cardiac surgery trials (loading dose plus continuous infusion regimens), but this data comes from an entirely different clinical context (perioperative cardioprotection) and should not be conflated with exercise-mimetic or performance-oriented research interest.

Protocol	Dose (experimental model only)	Duration (experimental model only)	Frequency (experimental model only)	Research Context
Low-Range Research Protocol	Rodent-model-derived low-dose range (mg/kg, not human-converted)	2-4 weeks (rodent studies)	Once daily (rodent studies)	Initial AMPK activation and oxidative gene expression studies.
Standard Research Protocol	Rodent-model-derived mid-dose range (mg/kg, not human-converted)	4-6 weeks (rodent studies)	Once daily (rodent studies)	Endurance and fat-oxidation research, as in Narkar et al. 2008.
Historical Clinical Research (Acadesine, cardiac surgery)	IV loading dose plus continuous infusion (per historical trial protocols)	Perioperative period only (hours, not weeks)	Single perioperative course	Historical human cardioprotection trials — distinct clinical context, not applicable to exercise-mimetic research interest.

Observed Side Effects in Research

• Hypotension reported at higher intravenous doses in some historical acadesine cardiac surgery trial contexts.
• Flushing reported in some historical acadesine cardiac surgery trial contexts.

These documented effects come from the acadesine human cardiac surgery trials — a clinical context entirely different from the exercise-mimetic or performance-oriented research interest in AICAR. No human safety data exists for AICAR in the context of chronic use, exercise-mimetic dosing, or performance-oriented use patterns. Safety information should not be extrapolated across these two distinct research contexts.

Compound Data

CAS Number

2627-69-2

Molecular Formula

C₉H₁₅N₄O₈P

Molecular Weight

Approximately 338.21 g/mol

Half-Life

Short — approximately 1 hour in humans (based on acadesine cardiac surgery trial pharmacokinetic data)

Synonyms

Acadesine, AICA ribonucleotide, N1-(β-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide (closely related but distinct from the AICA riboside form)

Research Classification

Nucleotide analogue, AMPK (AMP-activated protein kinase) activator

Scientific References

• [Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. 2008] — AMPK and PPARdelta agonists are exercise mimetics. — Cell — [Animal, landmark study]
• Multicentre Phase 3 acadesine perioperative cardioprotection trials (1990s–2000s) — investigated acadesine for reduction of ischemic injury during coronary artery bypass graft (CABG) surgery; overall Phase 3 endpoints not consistently met and development was discontinued without regulatory approval. — [Human RCT, historical, different indication]
• World Anti-Doping Agency (WADA) Prohibited List — AICAR listed under class S4, Hormone and Metabolic Modulators — [Regulatory / compliance reference]

*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*